KR102860817B1 - 트라디피턴트에 의한 치료 방법 - Google Patents

트라디피턴트에 의한 치료 방법

Info

Publication number
KR102860817B1
KR102860817B1 KR1020237043041A KR20237043041A KR102860817B1 KR 102860817 B1 KR102860817 B1 KR 102860817B1 KR 1020237043041 A KR1020237043041 A KR 1020237043041A KR 20237043041 A KR20237043041 A KR 20237043041A KR 102860817 B1 KR102860817 B1 KR 102860817B1
Authority
KR
South Korea
Prior art keywords
tradipitant
pharmaceutical composition
pruritus
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237043041A
Other languages
English (en)
Korean (ko)
Other versions
KR20230173743A (ko
Inventor
미하엘 에이치. 폴리머로폴로스
루이스 윌리엄 리카멜
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020257030197A priority Critical patent/KR20250136946A/ko
Publication of KR20230173743A publication Critical patent/KR20230173743A/ko
Application granted granted Critical
Publication of KR102860817B1 publication Critical patent/KR102860817B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237043041A 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법 Active KR102860817B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257030197A KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128,472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232,644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant
KR1020177026588A KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026588A Division KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257030197A Division KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Publications (2)

Publication Number Publication Date
KR20230173743A KR20230173743A (ko) 2023-12-27
KR102860817B1 true KR102860817B1 (ko) 2025-09-16

Family

ID=55629110

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020257030197A Pending KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020177026588A Ceased KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020237043041A Active KR102860817B1 (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020257030197A Pending KR20250136946A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법
KR1020177026588A Ceased KR20170122777A (ko) 2015-03-04 2016-03-04 트라디피턴트에 의한 치료 방법

Country Status (19)

Country Link
US (6) US10463655B2 (enExample)
EP (2) EP3265087B1 (enExample)
JP (4) JP6891385B2 (enExample)
KR (3) KR20250136946A (enExample)
CN (2) CN113262221A (enExample)
AU (4) AU2016226006B2 (enExample)
BR (1) BR112017018620A2 (enExample)
CA (2) CA2978736C (enExample)
CL (1) CL2017002238A1 (enExample)
DK (1) DK3265087T3 (enExample)
ES (1) ES2824552T3 (enExample)
HR (1) HRP20201627T1 (enExample)
HU (1) HUE050944T2 (enExample)
IL (1) IL254142B (enExample)
MX (2) MX385788B (enExample)
PT (1) PT3265087T (enExample)
RU (1) RU2770050C2 (enExample)
WO (1) WO2016141341A1 (enExample)
ZA (1) ZA201706059B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3265087T (pt) * 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
CN111093671A (zh) * 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
EP3801514A1 (en) 2018-06-08 2021-04-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
HRP20250097T1 (hr) * 2018-09-28 2025-03-28 Vanda Pharmaceuticals Inc. Primjena tradipitanta kod bolesti kretanja
EP3890735A1 (en) 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
IL295327A (en) 2020-02-25 2022-10-01 Vanda Pharmaceuticals Inc Improved treatment of atopic dermatitis with tradipitant
US20230145932A1 (en) * 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
EP4637766A1 (en) 2022-12-21 2025-10-29 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
DK1035115T3 (da) 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
ATE384053T1 (de) * 2002-04-26 2008-02-15 Lilly Co Eli Triazolderivate als tachykininrezeptor- antagonisten
CN1313450C (zh) 2002-04-26 2007-05-02 伊莱利利公司 速激肽受体拮抗剂
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4959336B2 (ja) 2003-10-24 2012-06-20 イーライ リリー アンド カンパニー ｛２−［１−（３，５−ビストリフルオロメチルベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾル−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの新規の結晶形態
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
CA2643130A1 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compounds and methods of treating disorders associated with activation of metachromatic cells
BRPI0721069A2 (pt) * 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
AU2010282483B2 (en) 2009-08-14 2014-09-04 Opko Health, Inc. Intravenous formulations of neurokinin-1 antagonists
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
RS55206B1 (sr) 2009-11-18 2017-01-31 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
US20150320866A1 (en) 2012-12-13 2015-11-12 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP2016523260A (ja) * 2013-06-24 2016-08-08 タイガーキャット ファーマ インコーポレイテッド そう痒におけるｎｋ−１受容体アンタゴニストのセルロピタントの使用
PT3265087T (pt) * 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
PT3383363T (pt) 2015-11-30 2021-03-03 Anacor Pharmaceuticals Inc Formulações farmacêuticas tópicas para o tratamento de afeções relacionadas com inflamações
CN115531553A (zh) 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
CN111093671A (zh) * 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
EP3801514A1 (en) * 2018-06-08 2021-04-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
HRP20250097T1 (hr) * 2018-09-28 2025-03-28 Vanda Pharmaceuticals Inc. Primjena tradipitanta kod bolesti kretanja
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
EP3890735A1 (en) * 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
European Neuropsychopharmacology, 2010, 20(2), 80-87
PloS one, 2010, 5(6), e10968*
Science, 2008, 319(5869), 1536-1539*

Also Published As

Publication number Publication date
AU2025210905A1 (en) 2025-08-21
AU2023233141A1 (en) 2023-10-12
CA3213864A1 (en) 2016-09-09
IL254142A0 (en) 2017-10-31
RU2017134443A (ru) 2019-04-04
ES2824552T3 (es) 2021-05-12
CN107427502A (zh) 2017-12-01
US12318375B2 (en) 2025-06-03
CN113262221A (zh) 2021-08-17
EP3730140A1 (en) 2020-10-28
HUE050944T2 (hu) 2021-01-28
CN107427502B (zh) 2021-06-04
EP3265087A1 (en) 2018-01-10
US10772880B2 (en) 2020-09-15
MX385788B (es) 2025-03-18
AU2023233141B2 (en) 2025-05-22
MX2021010460A (es) 2021-09-21
US11324735B2 (en) 2022-05-10
KR20170122777A (ko) 2017-11-06
CA2978736A1 (en) 2016-09-09
JP2018507243A (ja) 2018-03-15
BR112017018620A2 (pt) 2018-04-17
KR20230173743A (ko) 2023-12-27
US20220226295A1 (en) 2022-07-21
HK1248552A1 (zh) 2018-10-19
JP2023052486A (ja) 2023-04-11
JP2024074963A (ja) 2024-05-31
US20200360358A1 (en) 2020-11-19
US20190290626A1 (en) 2019-09-26
IL254142B (en) 2022-05-01
AU2021202956A1 (en) 2021-06-03
JP6891385B2 (ja) 2021-06-18
WO2016141341A1 (en) 2016-09-09
CA2978736C (en) 2023-11-07
JP2021073258A (ja) 2021-05-13
CL2017002238A1 (es) 2018-04-20
AU2016226006A1 (en) 2017-09-21
DK3265087T3 (da) 2020-10-19
RU2770050C2 (ru) 2022-04-14
NZ735121A (en) 2024-07-26
AU2021202956B2 (en) 2023-06-29
US20250205213A1 (en) 2025-06-26
RU2017134443A3 (enExample) 2019-09-05
PT3265087T (pt) 2020-10-15
US20180110761A1 (en) 2018-04-26
AU2016226006B2 (en) 2021-03-04
ZA201706059B (en) 2023-08-30
HRP20201627T1 (hr) 2021-02-19
MX2017011279A (es) 2018-01-25
KR20250136946A (ko) 2025-09-16
EP3265087B1 (en) 2020-07-22
US20190290625A1 (en) 2019-09-26
US10463655B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
KR102860817B1 (ko) 트라디피턴트에 의한 치료 방법
KR20090034810A (ko) 멜라토닌 효능제 치료
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
KR102311915B1 (ko) 만성 신장병의 진행 억제 또는 개선제
EA036347B1 (ru) Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы
US20220168318A1 (en) Pharmaceutical compositions and methods for treatment of insomnia
EP4615585A1 (en) Methods of using trazodone to reverse the effects of 5-ht2a receptor agonists
RU2810253C2 (ru) Способ лечения с применением традипитанта
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
HK1248552B (en) Method of treatment with tradipitant
JP2000515865A (ja) 過剰攻撃を処置する方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)